Onconetix Inc ONCO

Healthcare Biotechnology

Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5a-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

NDAQ:ONCO - Post by User

Onconetix Inc

Bullboard Posts

Next >>

Post by coolfooldumbguyon Jul 18, 2024 10:48am

44 Views

Post# 36138337

This stock is a good buy for me

bought 30000 shares at .235cents/share,and will keep it for the rest of this year.This company is working on ontology treatments,to do with prostate problems,so gets and do your own research on it.

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments